Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Osteosarcoma 1Neuroblastoma 1Multiple Myeloma 1Melanoma 1

Interventions

X-Rays 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Phantoms, Imaging 6Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4cixutumumab 3cabozantinib 3Temozolomide 3Leucovorin 3Filgrastim 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2merphos 2larotrectinib 2ixabepilone 2ivosidenib 2ensartinib 2dinutuximab 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteosarcoma × AP 1903 reagent × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡